Jiangxi Synergy Pharmaceutical's Celecoxib API Receives CDE Approval

Stock News06-01

Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient "Celecoxib" has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, as confirmed via the CDE's public registration information platform.

Celecoxib is primarily indicated for relieving the signs and symptoms of osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis, as well as for treating acute pain in adults.

The approval of the Celecoxib API signifies that the product meets China's relevant technical standards for drug evaluation and is cleared for use in domestically marketed pharmaceutical preparations.

This development is expected to aid the company in expanding the product's sales within the domestic market, fostering a favorable sales structure that operates concurrently in both domestic and international markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126013289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126013289","market":"nz","top_or_hot":-1,"title":"Jiangxi Synergy Pharmaceutical's Celecoxib API Receives CDE Approval","media":"Stock News","content":"<p>Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient \"Celecoxib\" has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, as confirmed via the CDE's public registration information platform.<br><br>Celecoxib is primarily indicated for relieving the signs and symptoms of osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis, as well as for treating acute pain in adults.<br><br>The approval of the Celecoxib API signifies that the product meets China's relevant technical standards for drug evaluation and is cleared for use in domestically marketed pharmaceutical preparations.<br><br>This development is expected to aid the company in expanding the product's sales within the domestic market, fostering a favorable sales structure that operates concurrently in both domestic and international markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Synergy Pharmaceutical's Celecoxib API Receives CDE Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Synergy Pharmaceutical's Celecoxib API Receives CDE Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient \"Celecoxib\" has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, as confirmed via the CDE's public registration information platform.<br><br>Celecoxib is primarily indicated for relieving the signs and symptoms of osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis, as well as for treating acute pain in adults.<br><br>The approval of the Celecoxib API signifies that the product meets China's relevant technical standards for drug evaluation and is cleared for use in domestically marketed pharmaceutical preparations.<br><br>This development is expected to aid the company in expanding the product's sales within the domestic market, fostering a favorable sales structure that operates concurrently in both domestic and international markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1223083913.SGD","symbol_name":"Schroder ISF Global Gold A Acc SGD-H","start_time":0,"source_url":"","article_id":"1126013289","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126013289","pubTimestamp":1780301065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient \"Celecoxib\" has been approved by the Center for Drug Evaluation (CDE)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300636":"同和药业","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","CDE":"科尔黛伦矿业","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU1223082196.USD":"施罗德环球黄金A Acc","BK4017":"黄金","BK0239":"医药制造"},"translate_title":"江西协同药业塞来昔布原料药获CDE批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300636":1,"CDE":1},"content_text":"Jiangxi Synergy Pharmaceutical Co.,Ltd. (300636.SZ) has announced that its application for the active pharmaceutical ingredient \"Celecoxib\" has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, as confirmed via the CDE's public registration information platform.Celecoxib is primarily indicated for relieving the signs and symptoms of osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis, as well as for treating acute pain in adults.The approval of the Celecoxib API signifies that the product meets China's relevant technical standards for drug evaluation and is cleared for use in domestically marketed pharmaceutical preparations.This development is expected to aid the company in expanding the product's sales within the domestic market, fostering a favorable sales structure that operates concurrently in both domestic and international markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126013289","isCrawlerRequest":true}